BioCentury
ARTICLE | Clinical News

CRS-207: Phase IIb started

February 17, 2014 8:00 AM UTC

Aduro began the open-label, North American Phase IIb ECLIPSE trial to compare CRS-207 plus GVAX Pancreas cancer vaccine and low-dose cyclophosphamide vs. CRS-207 alone or chemotherapy in about 240 previously treated metastatic pancreatic cancer patients. Patients in the combination arm will receive CRS-207 in weeks 7, 10, 13 and 16 and GVAX Pancreas plus cyclophosphamide in weeks 1 and 4. Patients will receive CRS-207 as monotherapy in weeks 1, 4, 7, 10, 13 and 16. ...